University of Manitoba

Theralase's topical Ruvidar® treatment demonstrated complete healing of HSV-1 cutaneous lesions in mice after four days of application, marking a significant breakthrough in herpes treatment.

Advanced risk stratification models are enabling precise identification of high-risk CKD patients and connecting them with appropriate therapies, bridging the gap between diagnostics and treatment.